Literature DB >> 18668129

Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.

J S Khorashad, V A De Melo, H Fiegler, G Gerrard, D Marin, J F Apperley, J M Goldman, L Foroni, A G Reid.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18668129     DOI： 10.1038/leu.2008.210

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors:  Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

Review 2.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 3.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

4.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Authors:  Elisabeth Bolton-Gillespie; Mirle Schemionek; Hans-Ulrich Klein; Sylwia Flis; Grazyna Hoser; Thoralf Lange; Margaret Nieborowska-Skorska; Jacqueline Maier; Linda Kerstiens; Mateusz Koptyra; Martin C Müller; Hardik Modi; Tomasz Stoklosa; Ilona Seferynska; Ravi Bhatia; Tessa L Holyoake; Steffen Koschmieder; Tomasz Skorski
Journal:  Blood       Date:  2013-03-29       Impact factor: 22.113

Review 6.  Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.

Authors:  Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2011-02

7.  Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate.

Authors:  Veera S Nadarajan; Chin-Lee Phan; Chow-Hiang Ang; Kai-Ling Liang; Gin-Gin Gan; Ping-Chong Bee; Zubaidah Zakaria
Journal:  Int J Hematol       Date:  2011-03-09       Impact factor: 2.490

Review 8.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

9.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

10.  SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

Authors:  Daniel Nowak; Seishi Ogawa; Markus Müschen; Motohiro Kato; Norihiko Kawamata; Antonie Meixel; Verena Nowak; Han S Kim; Sharon Kang; Ronald Paquette; Mi-Sook Chang; Nils H Thoennissen; Nils H Thoenissen; Max Mossner; Wolf-Karsten Hofmann; Alexander Kohlmann; Tamara Weiss; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Blood       Date:  2009-12-02       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.